Achillion to Present at Upcoming Conferences

NEW HAVEN, Conn., Feb. 26 /PRNewswire-FirstCall/ -- Achillion Pharmaceuticals, Inc., (NASDAQ:ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, Chief Executive Officer of Achillion, will be presenting a corporate overview and update on the Company's clinical programs in HIV, HCV and serious bacterial infections at the following upcoming investment conferences:

    -- SIGnificant Investment Options in Healthcare by Susquehanna Financial
       Group -- March 1, 2007 at 1:30 PM at the Omni Berkshire Place Hotel in
       New York City;
    -- Cowen and Company Annual Healthcare Conference -- March 13, 2007 at
       8:00 AM at the Marriott Copley Place in Boston.

In addition, Achillion senior scientists will participate in the following panel discussions during the SIGnificant Investment Options in Healthcare conference:

    -- John Pottage, M.D., Chief Medical Officer, will participate in a panel
       discussion at 8:00 AM entitled, "Antibiotic Resistance:
       Challenges/Opportunities in MRSA, C. difficile, and S. pneumonia";
    -- Milind S. Deshpande, Ph.D., Achillion's Chief Scientific Officer, will
       participate in a panel discussion at 10:00 AM entitled, "Hepatitis C
       Virus: What to Target -- Proteases, Polymerases or Replicases?"

    About Achillion

Achillion is a biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for infectious diseases. Achillion is currently developing treatments for HIV infection, chronic hepatitis C infection and serious hospital-based bacterial infections. For more information on Achillion Pharmaceuticals, please visit the company's web site at www.achillion.com or call Achillion at 1-203-624-7000. ACHN-G

    Contact:                           Media:
    Mary Kay Fenton                    Kari Watson
    Achillion Pharmaceuticals, Inc.    MacDougall Biomedical Communications
    Tel. (203) 624-7000                Tel. (508) 647-0209
    mfenton@achillion.com              kwatson@macbiocom.com

Source: Achillion Pharmaceuticals, Inc.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here